ANTX

AN2 Therapeutics, Inc. · NASDAQ

Sector Health Technology
Industry Biotechnology
Website an2therapeutics.com
Employees(FY) 35
ISIN US0373261058

Performance

+22.64%

+23.81%

-42.73%

-93.66%

YTD

-92.07%

Profile

AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, which is in a pivotal Phase 2/3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.

Advanced Technical Analysis

Technical Analysis of ANTX 2024-11-20

The stock exhibits a generally bullish sentiment with a Moving Average Score of 70 indicating strong upward momentum, while the Oscillators Score of 60 and Technical Score of 65 further support a positive outlook, suggesting a favorable environment for potential price appreciation. Overall, the combined scores reflect a solid bullish trend in th...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of ANTX

Stock Rank

Recent News & Updates

2024-11-13 18:00
AN2 Therapeutics to Participate at Upcoming Investor Conferences(Businesswire)
2024-11-13 03:00
AN2 Therapeutics Reports Third Quarter 2024 Financial Results, Provides Important EBO-301 Update and Highlights Progress Across Boron Chemistry Pipeline(Businesswire)
2024-10-16 19:00
AN2 Therapeutics Receives Continuation Grant to Discover Novel Boron Based Therapies for Tuberculosis (caused by Mycobacterium tuberculosis) and Malaria(Businesswire)
2024-08-28 04:00
AN2 Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference(Businesswire)
2024-08-18 22:29
AN2 Therapeutics (ANTX) Plunges 66% in a Month: Here's Why(Yahoo Finance)
2024-08-15 19:00
AN2 Therapeutics Adopts Limited Duration Stockholder Rights Plan(Businesswire)
2024-08-13 04:01
AN2 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business and Scientific Highlights(Businesswire)
2024-08-09 00:15
Lung Disease Focused AN2 Therapeutics' Lackluster Data Prompts To Stop Phase 3 Study Of Lung Infection Candidate, Halves Workforce(Yahoo Finance)
2024-08-08 21:33
AN2 slashes staff by 50% after lead antibiotic flunks in Phase II/III trial(Yahoo Finance)
2024-08-08 04:30
AN2 Therapeutics Provides Update on EBO-301 Phase 2/3 Study Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium Complex (MAC) Lung Disease(Businesswire)
2024-07-02 21:50
Intuit initiated, Charter downgraded: Wall Street's top analyst calls(Yahoo Finance)
2024-05-20 21:35
Down -5.51% in 4 Weeks, Here's Why AN2 Therapeutics (ANTX) Looks Ripe for a Turnaround(Zacks)
2024-05-14 10:55
ANTX Stock Earnings: AN2 Therapeutics Beats EPS for Q1 2024(Investorplace)
2024-05-14 04:01
AN2 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business and Scientific Highlights(Businesswire)
2024-03-28 11:53
ANTX Stock Earnings: AN2 Therapeutics Beats EPS for Q4 2023(Investorplace)
2024-03-28 04:10
AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights(Businesswire)
2024-03-21 19:00
Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results(Prnewswire)
2024-02-21 15:21
13 Best Falling Stocks To Buy Right Now(Yahoo Finance)
2024-02-12 07:04
UPDATE 1-AN2 Therapeutics to pause lung disease study enrollment(Reuters)
2024-02-12 06:54
AN2 Therapeutics to pause lung disease study enrollment(Reuters)
2024-02-12 06:45
AN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung Disease(Business Wire)
2024-02-11 21:03
AN2 Therapeutics Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm(Globenewswire)
2024-02-11 17:45
AN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung Disease(Businesswire)
2024-02-01 07:29
We're Not Very Worried About AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Rate(Simply Wall St.)
2024-01-30 16:10
AN2 Therapeutics to Present at Oppenheimer Healthcare Life Sciences Conference(Business Wire)
2024-01-30 03:10
AN2 Therapeutics to Present at Oppenheimer Healthcare Life Sciences Conference(Businesswire)
2024-01-19 06:34
Daily â€“ Vickers Top Buyers & Sellers for 01/19/2024(Argus Research)
2024-01-12 09:02
AN2 Therapeutics Inc Chief Strategy Officer Kevin Krause Sells 7,417 Shares(GuruFocus.com)
2024-01-10 08:50
Recent Price Trend in AN2 Therapeutics, Inc. (ANTX) is Your Friend, Here's Why(Zacks)
2023-11-12 07:06
One AN2 Therapeutics Insider Raised Their Stake In The Previous Year(Simply Wall St.)

Page 1 of 3

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.